Impax Asset Management Group plc Acquires 100,000 Shares of Enovis Corporation $ENOV

Impax Asset Management Group plc lifted its stake in Enovis Corporation (NYSE:ENOV) by 47.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 310,630 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Impax Asset Management Group plc owned approximately 0.54% of Enovis worth $9,425,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its holdings in Enovis by 42.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. Elevation Point Wealth Partners LLC purchased a new stake in shares of Enovis in the second quarter worth about $46,000. SJS Investment Consulting Inc. boosted its position in shares of Enovis by 30,340.0% in the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after acquiring an additional 1,517 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in shares of Enovis by 235.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock valued at $52,000 after acquiring an additional 1,195 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Stock Up 0.9%

Shares of NYSE:ENOV opened at $22.77 on Thursday. The firm has a market capitalization of $1.30 billion, a PE ratio of -0.96 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. Enovis Corporation has a 52-week low of $21.00 and a 52-week high of $44.76. The firm has a fifty day moving average of $25.32 and a 200 day moving average of $28.57.

Insider Activity

In other news, insider John Kleckner bought 2,468 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was acquired at an average price of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider directly owned 12,302 shares in the company, valued at $372,996.64. This represents a 25.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total transaction of $27,172.80. The SEC filing for this sale provides additional information. 2.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on ENOV shares. Wells Fargo & Company upped their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. UBS Group reaffirmed a “buy” rating and issued a $50.00 price target on shares of Enovis in a report on Monday, January 5th. Canaccord Genuity Group dropped their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Evercore restated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, BTIG Research initiated coverage on Enovis in a report on Tuesday, January 6th. They issued a “buy” rating and a $41.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.71.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.